

It was a great privilege for me to be given an opportunity by Malaysia Society of Haematology (MSH) education committee to attend 24th Annual John Goldman Conference on Chronic Myeloid Leukemia: Biology and Therapy which took place from October 21 to 23, 2022 in Mandelieu-La Napoule, France. After two years of virtual conferences, it was a real pleasure to have a three-day physical conference. It offered scientists and clinicians from 41 nations around the world an excellent platform to network and discuss topics related to Chronic Myeloid Leukemia disciplines including biology, immunology, genetics, therapy, and management.

My journey started by preparing two abstracts and posters presentation on “Molecular Landscape Of Patients With Chronic Myeloid Leukaemia Who Failed Treatment-Free Remission, A Preliminary Observation” And “A Real-World Study Of End Tyrosine Kinase Inhibitor In Chronic Myeloid Leukaemia (Entic) In Malaysia”. On the first day of conference during poster walk, I shared with distinguished special lecturers from CML scientific community our multi-centers in Malaysia experience on treatment free remission (TFR) and the molecular landscape on patients who failed TFR. This poster had won an ESH award.

In term of course, the organizing committee had put forward a comprehensive scientific programme with fascinating combinations of plenary and symposia presentations that cover a variety of subjects. Keynote speakers discuss metabolomics in myeloid malignancies, including the metabolism of CML and new therapeutic targets for the elimination of leukemic cells. Speakers participated in a "meet the expert" session to discuss the biology of leukaemia, the practical applications of multidisciplinary approaches to the disease, including leukaemia stem cell research, and new directions in the research and development of cancer drugs.

For further discussion, there were also interactive sessions and a meet the expert session. Chief investigators Prof. Susanne Saussele and Prof. Delphine Rea from the Long-Term Follow-Up of the French Stop Imatinib (STIM1) study and the Pan European Stop Tyrosine Kinase Inhibitor Trial in Chronic Myeloid Leukemia: The EURO-SKI study presented their updated analysis and shared their experiences on TFR during the meet the expert session. Additionally, Dr. Dennis Dong Hwan Kim of Toronto presented the final results of the TKI discontinuation trial with dasatinib for the second effort at TFR after the first attempt with imatinib failed. Dr. Miriam Leza of Bologna presented her ten years of expertise in TFR for CML (Bologna). A workshop on 3D genomics and nuclear organization including Next-generation cytogenomics in leukemia was held, it is good to explore the opportunities for diagnosis and discovery in CML.

In summary, this was a very beneficial and fruitful conference for me, especially on my pathway in conducting further research study. I would like to take this opportunity to express my gratitude to MSH for sponsoring me to this event and to present my poster presentation there. It was a great opportunity to present my work, exchange with peers and interact face-face with global experts in the CML filed. It was indeed a great educational experience and much more.

By: Chong Siew Lian, Hospital Ampang.

